PDT Partners’s Acceleron Pharma XLRN Stock Holding History

PDT Partners’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-4,110	Closed	-$516K	–	977
2021 Q2	$516K	Buy	+4,110	New	+$518K	0.03%	509
2020 Q1	–	Sell	-5,914	Closed	-$314K	–	912
2019 Q4	$314K	Buy	+5,914	New	+$270K	0.02%	528
2018 Q2	–	Sell	-64,166	Closed	-$2.51M	–	603
2018 Q1	$2.51M	Sell	64,166 -202	-0.3%	-$8.59K	0.08%	243
2017 Q4	$2.73M	Buy	64,368 +87	+0.1%	+$3.26K	0.08%	258
2017 Q3	$2.4M	Hold	64,281	–	–	0.08%	259
2017 Q2	$1.95M	Sell	64,281 -500	-0.8%	-$14.5K	0.08%	256
2017 Q1	$1.72M	Buy	64,781 +18,080	+39%	+$476K	0.09%	246
2016 Q4	$1.19M	Sell	46,701 -5,400	-10%	-$171K	0.08%	316
2016 Q3	$1.89M	Hold	52,101	–	–	0.11%	230
2016 Q2	$1.77M	Sell	52,101 -6,364	-11%	-$207K	0.14%	208
2016 Q1	$1.54M	Buy	58,465 +33,195	+131%	+$965K	0.1%	262
2015 Q4	$1.23M	Buy	+25,270	New	+$909K	0.17%	190
2014 Q3	–	Sell	-49,761	Closed	-$1.69M	–	1676
2014 Q2	$1.69M	Buy	49,761 +33,462	+205%	+$1.12M	0.05%	499
2014 Q1	$562K	Buy	+16,299	New	+$736K	0.01%	884

Other funds holding XLRN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

PDT Partners's XLRN Position: Q3 2021 in Review

PDT Partners sold out of Acceleron Pharma (XLRN) in Q3 2021, closing a stake of 4,110 shares — an estimated $516K sold.

PDT Partners first reported a position in XLRN in Q1 2014 and held it in 14 quarters. The position peaked at $2.73M in Q4 2017. 330 funds tracked by Wall St. Rank hold XLRN as of Q3 2021.

PDT Partners reported no remaining Acceleron Pharma position as of Q3 2021 after selling out during the quarter.
PDT Partners sold 4,110 Acceleron Pharma shares in Q3 2021, an estimated $516K.
PDT Partners first reported a position in Acceleron Pharma in Q1 2014 and held it in 14 quarters.
PDT Partners's Acceleron Pharma position peaked at $2.73M in Q4 2017.
330 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2021.

Based on PDT Partners's 13F filing for Q3 2021, filed 15 Nov 2021.